Phase 2 Start
AGMB: Phase 2 Start: A Phase 2b, Randomized, Placebo-controlled, Double-blind, Dose-ranging Trial to Assess the Efficacy
October 30, 2026 · fibrostenosing. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- October 30, 2026
- Company
- AgomAb Therapeutics NV (AGMB)
- Drug
- fibrostenosing
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 2 Start~month
Phase 2 Start: A Phase 2b, Randomized, Placebo-controlled, Double-blind, Dose-ranging Trial to Assess the Efficacy
- Drug
- fibrostenosing
- Indication
- Fibrostenotic Crohn's Disease